Skip Nav Destination
Issues
1 November 2015
-
Cover Image
Cover Image
Tankyrase inhibitors, which are potential therapeutics in WNT-dependent cancers, induce cytoplasmic puncta (degradasomes) consisting of components of the signal-limiting WNT/β-catenin destruction complex. 3D structured illumination microscopy of SW480 colon carcinoma cells reveals an irregular shape of the induced degradasomes and a non-homogeneous distribution of tankyrase (green), β-catenin (white) and AXIN2 (red) in subdomains. Nuclei are in blue. Thorvaldsen and colleagues (p. 1487), demonstrate that β-catenin is rapidly turned over in degradasomes upon tankyrase inhibition and provide a direct mechanistic link between degradasome formation and reduced WNT signaling in colon carcinoma cells. - PDF Icon PDF LinkTable of Contents
ISSN 1541-7786
EISSN 1557-3125
Journal Archive
Molecular Cancer Research (2002-Present; volumes 1-current)
(ISSN 0008-5472) Published monthly since November, 2002.Cell Growth & Differentiation (1990-2002; volumes 1-13)
(ISSN 1044-9523) Published monthly 1990- September, 2002.Table of Contents
Highlights
Review
Commentary
Chromatin, Gene, and RNA Regulation
Association of HO-1 and BRCA1 Is Critical for the Maintenance of Cellular Homeostasis in Prostate Cancer
Estefanía Labanca; Paola De Luca; Geraldine Gueron; Alejandra Paez; Cristian P. Moiola; Cintia Massillo; Juliana Porretti; Jimena Giudice; Florencia Zalazar; Nora Navone; Elba Vazquez; Adriana De Siervi
DNA Damage and Repair
Author Choice
Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors
Todd A. Hopkins; Yan Shi; Luis E. Rodriguez; Larry R. Solomon; Cherrie K. Donawho; Enrico L. DiGiammarino; Sanjay C. Panchal; Julie L. Wilsbacher; Wenqing Gao; Amanda M. Olson; DeAnne F. Stolarik; Donald J. Osterling; Eric F. Johnson; David Maag
Oncogenes and Tumor Suppressors
Signal Transduction
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.